Literature DB >> 21900196

Low telomerase activity in CD4+ regulatory T cells in patients with severe chronic GVHD after hematopoietic stem cell transplantation.

Yutaka Kawano1, Haesook T Kim, Ken-Ichi Matsuoka, Gregory Bascug, Sean McDonough, Vincent T Ho, Corey Cutler, John Koreth, Edwin P Alyea, Joseph H Antin, Robert J Soiffer, Jerome Ritz.   

Abstract

CD4(+)CD25(+)Foxp3(+) regulatory T cells (Treg) play an important role in the control of chronic graft-versus-host disease (cGVHD). In this study, we examined telomere length and telomerase activity of Treg and conventional CD4(+) T cells (Tcon) in 61 patients who survived more than 2 years after allogeneic hematopoietic stem cell transplantation. Cell proliferation and expression of Bcl-2 were also measured in each subset. Treg telomere length was shorter and Treg telomerase activity was increased compared with Tcon (P < .0001). After transplantation, Treg were also more highly proliferative than Tcon (P < .0001). Treg number, telomerase activity, and expression of Bcl-2 were each inversely associated with severity of cGVHD. These data indicate that activation of telomerase is not sufficient to prevent telomere shortening in highly proliferative Treg. However, telomerase activation is associated with increased Bcl-2 expression and higher Treg numbers in patients with no or mild cGVHD. In contrast, patients with moderate or severe cGVHD have fewer Treg with lower levels of telomerase activity and Bcl-2 expression. These results suggest that failure to activate Treg telomerase may restrict proliferative capacity and increase apoptotic susceptibility, resulting in the loss of peripheral tolerance and the development of cGVHD.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21900196      PMCID: PMC3208307          DOI: 10.1182/blood-2011-06-362137

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  43 in total

Review 1.  Nonradioactive detection of telomerase activity using a PCR-ELISA-based telomeric repeat amplification protocol.

Authors:  Thomas Emrich; Gerlinde Karl
Journal:  Methods Mol Biol       Date:  2002

2.  CD25+ immunoregulatory T-cells of donor origin suppress alloreactivity after BMT.

Authors:  Bryon D Johnson; Marja C Konkol; Robert L Truitt
Journal:  Biol Blood Marrow Transplant       Date:  2002       Impact factor: 5.742

3.  Akt protein kinase enhances human telomerase activity through phosphorylation of telomerase reverse transcriptase subunit.

Authors:  S S Kang; T Kwon; D Y Kwon; S I Do
Journal:  J Biol Chem       Date:  1999-05-07       Impact factor: 5.157

4.  Stable association of hsp90 and p23, but Not hsp70, with active human telomerase.

Authors:  H L Forsythe; J L Jarvis; J W Turner; L W Elmore; S E Holt
Journal:  J Biol Chem       Date:  2001-03-23       Impact factor: 5.157

5.  Sp1 cooperates with c-Myc to activate transcription of the human telomerase reverse transcriptase gene (hTERT).

Authors:  S Kyo; M Takakura; T Taira; T Kanaya; H Itoh; M Yutsudo; H Ariga; M Inoue
Journal:  Nucleic Acids Res       Date:  2000-02-01       Impact factor: 16.971

6.  The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality.

Authors:  Patricia A Taylor; Christopher J Lees; Bruce R Blazar
Journal:  Blood       Date:  2002-05-15       Impact factor: 22.113

7.  Ectopic hTERT expression extends the life span of human CD4+ helper and regulatory T-cell clones and confers resistance to oxidative stress-induced apoptosis.

Authors:  Rosalie M Luiten; Jérome Péne; Hans Yssel; Hergen Spits
Journal:  Blood       Date:  2003-02-13       Impact factor: 22.113

8.  Telomere dysfunction promotes non-reciprocal translocations and epithelial cancers in mice.

Authors:  S E Artandi; S Chang; S L Lee; S Alson; G J Gottlieb; L Chin; R A DePinho
Journal:  Nature       Date:  2000-08-10       Impact factor: 49.962

9.  CD4(+)CD25(+) immunoregulatory T Cells: new therapeutics for graft-versus-host disease.

Authors:  José L Cohen; Aurélie Trenado; Douglas Vasey; David Klatzmann; Benoît L Salomon
Journal:  J Exp Med       Date:  2002-08-05       Impact factor: 14.307

10.  Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis.

Authors:  Vissia Viglietta; Clare Baecher-Allan; Howard L Weiner; David A Hafler
Journal:  J Exp Med       Date:  2004-04-05       Impact factor: 14.307

View more
  21 in total

1.  Increased mitochondrial apoptotic priming of human regulatory T cells after allogeneic hematopoietic stem cell transplantation.

Authors:  Kazuyuki Murase; Haesook T Kim; O R Gregory Bascug; Yutaka Kawano; Jeremy Ryan; Ken-ichi Matsuoka; Matthew S Davids; John Koreth; Vincent T Ho; Corey Cutler; Philippe Armand; Edwin P Alyea; Bruce R Blazar; Joseph H Antin; Robert J Soiffer; Anthony Letai; Jerome Ritz
Journal:  Haematologica       Date:  2014-05-23       Impact factor: 9.941

2.  Pre-transplant donor CD4- invariant NKT cell expansion capacity predicts the occurrence of acute graft-versus-host disease.

Authors:  M-T Rubio; M Bouillié; N Bouazza; T Coman; H Trebeden-Nègre; A Gomez; F Suarez; D Sibon; A Brignier; E Paubelle; S Nguyen-Khoc; M Cavazzana; O Lantz; M Mohty; S Urien; O Hermine
Journal:  Leukemia       Date:  2016-10-14       Impact factor: 11.528

3.  Reconstitution and clinical significance of T cell subsets in the early stage after related HLA-mismatched peripheral blood hematopoietic SCT without T-cell depletion in vitro.

Authors:  Nannan Pang; Xianlin Duan; Ming Jiang; Jianhua Qu; Hailong Yuan; Jianli Xu; Haizhou Cao; Gang Chen
Journal:  Int J Clin Exp Pathol       Date:  2015-08-01

Review 4.  B-cell targeting in chronic graft-versus-host disease.

Authors:  Robert Zeiser; Stefanie Sarantopoulos; Bruce R Blazar
Journal:  Blood       Date:  2018-02-01       Impact factor: 22.113

Review 5.  Low-dose interleukin-2 as a modulator of Treg homeostasis after HSCT: current understanding and future perspectives.

Authors:  Ken-Ichi Matsuoka
Journal:  Int J Hematol       Date:  2017-12-12       Impact factor: 2.490

Review 6.  Thinking out of the box--new approaches to controlling GVHD.

Authors:  Frédéric Baron; Stéphanie Humblet-Baron; Grégory Ehx; Sophie Servais; Muriel Hannon; Ludovic Belle; Chantal Lechanteur; Alexandra Briquet; Olivier Giet; Etienne Baudoux; Evelyne Willems; Yves Beguin
Journal:  Curr Hematol Malig Rep       Date:  2014-03       Impact factor: 3.952

Review 7.  National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Immune Dysregulation and Pathobiology Working Group Report.

Authors:  Juan Gea-Banacloche; Krishna V Komanduri; Paul Carpenter; Sophie Paczesny; Stefanie Sarantopoulos; Jo-Anne Young; Nahed El Kassar; Robert Q Le; Kirk R Schultz; Linda M Griffith; Bipin N Savani; John R Wingard
Journal:  Biol Blood Marrow Transplant       Date:  2016-10-14       Impact factor: 5.742

Review 8.  Chronic graft-versus-host disease: biological insights from preclinical and clinical studies.

Authors:  Kelli P A MacDonald; Geoffrey R Hill; Bruce R Blazar
Journal:  Blood       Date:  2016-11-07       Impact factor: 22.113

Review 9.  Mechanistic approaches for the prevention and treatment of chronic GVHD.

Authors:  Corey S Cutler; John Koreth; Jerome Ritz
Journal:  Blood       Date:  2016-11-07       Impact factor: 22.113

10.  Bim regulates the survival and suppressive capability of CD8+ FOXP3+ regulatory T cells during murine GVHD.

Authors:  Kimberle Agle; Benjamin G Vincent; Clint Piper; Ludovic Belle; Vivian Zhou; Warren Shlomchik; Jonathan S Serody; William R Drobyski
Journal:  Blood       Date:  2018-05-16       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.